The paper appeared a few months before the EMPA-REG OUTCOME trial revealed the potential of a new drug class, the SGLT2 inhibitors, in preventing hospitalization for heart failure.
Welcome to Paper of the Week, which looks back at research and commentary of the past 25 years in The American Journal of Managed Care® and why it matters today.
This week’s paper comes from our January 2015 issue. The authors of “Disease-Modifying Therapy and Hospitalization Risk in Heart Failure Patients” discuss the high cost of heart failure to the health system. They found that some treatments, such as ACE inhibitors or ARBs, had potential in preventing heart failure in Medicaid patients in managed care, but the projected savings were relatively modest.
The paper appeared a few months before the EMPA-REG OUTCOME trial revealed the potential of a new drug class, the SGLT2 inhibitors, in preventing hospitalization for heart failure.
For the full paper, visit ajmc.com.
Managed Care Reflections: A Q&A With Dora Hughes, MD, MPH
September 4th 2025To mark the 30th anniversary of The American Journal of Managed Care, each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The September issue features a conversation with Dora Hughes, MD, MPH, chief medical officer and director of the Center for Clinical Standards and Quality at CMS.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
Finerenone Demonstrates Safety and Efficacy in Heart Failure When Combined With Diuretics
August 13th 2025Clinical trial results establish the safety and efficacy of finerenone to help preserve potassium levels and reduce sodium in patients on diuretics with heart failure and mildly reduced ejection fraction or preserved ejection fraction.
Read More